SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neopath (NPTH)
NPTH 0.0006000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cytotekk who wrote (121)4/11/1998 12:56:00 PM
From: Sigmund  Read Replies (1) of 178
 
<<<Papnet is a system that is too costly<<<

True but the same can be said for AutoPap too although obviously not to the same extent.

I don't see how primary screening contributes much to improved diagnosis. It eliminates those slides which have nothing on them so that doesn't identify any cancers or precancers. Do you disagree with this?

How does it improve diagnosis?

And it certainly doesn't save the labs any money.

So that is why I conclude that it is noneconomic at this point in time.

Others will develop economic approaches for sure.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News